Preliminary investigation of contrast media dose for sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI

Preliminary investigation of contrast media dose for sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI - Sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009795

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain tumor

Interventions

Preliminary investigate possibility of reducing half dose (0.05mmol/kg) in perfusion MRI and 3D-MR DSA, respectively. And comparing single dose(0.1mmol/kg) with half dose. Secondly, investigate dose p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Suspect brain tumor pts or follow up of brain tumor 2) Over 20 years old 3) Accept regardless of gender 4) Clear consciousness

Exclusion criteria

Exclusion criteria: 1) Contraindication of MRI 2) Allergy to Gd contrast media 3) Asthma 4) Severe renal disease 5) During pregnancy or lactation 6) Investigator make a judgmental decision as unsuitableness

Design outcomes

Primary

Measure	Time frame
Conduct a qualitative assessment of Perfusion MRI and 3DMR DSA	—

Secondary

Measure	Time frame
CNR of gray matter and white matter SNR of gray matter and white matter Adverse drug reaction to the contrast agent	—

Countries

Japan

Contacts

Public ContactKeigo Shimoji

Juntendo Univ. Department of Radiology

kshimoji@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026